EUDA Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen

EUDA (NASDAQ: EUDA) launched a comprehensive stem cell therapy platform and opened its first longevity clinic in Shenzhen on Dec 23, 2025, accelerating its regenerative-medicine strategy.

Rhea-AI Summary

EUDA (NASDAQ: EUDA) launched a comprehensive stem cell therapy platform and opened its first longevity clinic in Shenzhen on Dec 23, 2025, accelerating its regenerative-medicine strategy.

The company is upgrading Shenzhen Inno’s cGMP facility into a production and innovation center integrating GO POSB’s iPSC platform and technologies from two Japanese partners to support iPSC expansion, stem cell preparation and T-cell immunotherapies. EUDA also holds distribution rights for Shenzhen Inno’s T-cell immunotherapies and stated an intention to acquire GO POSB. The Shenzhen clinic will offer advanced cell therapies, AI-guided life-cycle management, and integrated Eastern/Western/functional medicine.

Positive

• Launched comprehensive stem cell therapy platform (Dec 23, 2025)
• Established first Shenzhen longevity clinic offering integrated services
• Upgrading Shenzhen Inno cGMP facility into production/innovation center
• Holds distribution rights for T-cell immunotherapies from Shenzhen Inno
• Integrates GO POSB iPSC platform with Japanese partner technologies

Negative

• Intention to acquire GO POSB is announced but not completed

Argus Dec 23 session

+41.18% close to close Open Argus

Details

News Market Reaction – EUDA

On Dec 23, the day this news came out, EUDA closed 41.18% above the previous close.

Data tracked by StockTitan Argus for the Dec 23 session.

Key Figures

Japanese technology partners: 2 partners Shenzhen longevity clinic: 1 clinic

Japanese technology partners

2 partners

Advanced stem cell technologies sourced from two Japanese partners

Shenzhen longevity clinic

1 clinic

First comprehensive longevity clinic established in Shenzhen, China

Historical Context

5 past events · Latest: Dec 22

5 events

1. Dec 22

   Token integration

   24h Move

   -51.4%

   Full integration of QB utility token into digital health and rewards platform.

2. Dec 08

   Token plans

   24h Move

   +8.5%

   Planned integration of QB utility token and digital asset treasury strategy.

3. Dec 05

   Financing agreement

   24h Move

   -6.8%

   Convertible warrant financing under Form F-3 shelf to fund regional expansion.

4. Oct 23

   India expansion

   24h Move

   -15.5%

   CK Health Plus master license and partnership to expand into India.

5. Oct 20

   License win

   24h Move

   +1.8%

   Malaysia direct selling license supporting longevity business growth.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cGMP, induced pluripotent stem cell, iPSC, T-cell immunotherapies, +2 more

6 terms

cGMP technical

"EUDA is upgrading Shenzhen Inno’s cGMP facility in Shenzhen to create a state-of-the-art"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

induced pluripotent stem cell medical

"GO POSB’s proprietary induced pluripotent stem cell (“iPSC”) technological platform with advanced"

Cells taken from an adult (such as skin or blood) that scientists ‘reprogram’ so they behave like versatile early-stage cells capable of becoming many different cell types in the body. For investors, these cells matter because they enable development of personalized therapies, safer and faster drug testing, and potential regenerative treatments—like resetting a gadget to factory mode so it can run many different apps—creating new commercial opportunities and affecting biotech valuation and risk.

iPSC medical

"The Company and its partners will also explore cell-based solutions using iPSC technology,"

Induced pluripotent stem cells (iPSCs) are ordinary adult cells that scientists have reprogrammed back into a versatile, embryonic-like state so they can become many different cell types. Think of them as factory-reset cells that can be turned into heart, nerve, or blood cells for testing drugs, modeling diseases, or developing cell therapies. For investors, iPSCs signal potential high-reward opportunities in new treatments and research tools but also carry technical, manufacturing and regulatory risks that affect commercial prospects.

T-cell immunotherapies medical

"acquisition of distribution rights for T-cell immunotherapies developed by Shenzhen Inno Immune"

Therapies that use or modify a patient’s T-cells — a type of immune cell — to recognize and attack disease, most often cancer. Think of it as training and equipping a person’s internal soldiers to find a hidden enemy; investors watch these therapies because successful trials or approvals can create high-value medicines, while setbacks, manufacturing challenges and regulatory hurdles can sharply change a company’s outlook.

autologous cellular therapeutic medical

"Shenzhen Inno), a developer of autologous cellular therapeutic and customized medicines for a"

An autologous cellular therapeutic is a medical treatment made from a patient’s own cells that are collected, modified or expanded, and then re‑introduced to treat disease. For investors this matters because these products act like a custom‑tailored suit—offering lower risk of immune rejection but requiring individualized manufacturing, complex logistics and often higher per‑patient costs, which affect pricing, scalability and regulatory pathways.

immune cell therapies medical

"supporting iPSC expansion, stem cell preparation, immune cell therapies, and the development"

Immune cell therapies are medicines made by taking a person’s or donor’s immune cells, training, modifying or multiplying them in a lab, and then returning them to the body so the cells can better find and destroy disease such as cancer or viral infections. Investors care because these treatments can deliver dramatic patient benefits and premium pricing like a breakthrough product, but they also carry high research, manufacturing, and regulatory risks—think of it as training a specialized army that’s expensive and complex to equip and deploy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SINGAPORE, Dec. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced a significant acceleration of its longevity and regenerative medicine strategy with the launch of a comprehensive stem cell therapy platform and establishment of its first clinic in Shenzhen, China.

This strategic advancement builds on the Company’s earlier acquisition of distribution rights for T-cell immunotherapies developed by Shenzhen Inno Immune Co. Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in China, and its announced intention to acquire GO POSB Organoids Pte Ltd. (“GO POSB”), a biotechnology company formed in Singapore.

Integrated Production and Innovation Center

EUDA is upgrading Shenzhen Inno’s cGMP facility in Shenzhen to create a state-of-the-art production and innovation center for stem cell treatments. This advancement incorporates GO POSB’s proprietary induced pluripotent stem cell (“iPSC”) technological platform with advanced stem cell technologies sourced from two Japanese partners, including Japan Early Light Medical Corporation. The enhanced cGMP facility will be essential for supporting iPSC expansion, stem cell preparation, immune cell therapies, and the development of new treatments focused on immune health, skin health, and healthy aging. The Company and its partners will also explore cell-based solutions using iPSC technology, which converts human blood cells into stem cells capable of becoming nearly any cell type.

Establishment of Shenzhen Longevity Clinic

In parallel with the upgrade of Shenzhen Inno’s cGMP facility, EUDA, in partnership with KB International Ltd., established a new longevity clinic in Shenzhen. This clinic is strategically positioned to be the first in the region to comprehensively introduce Japanese longevity healthcare technologies. It will offer a differentiated portfolio of services, including:

• Advanced stem cell and T-cell immunotherapies produced at the upgraded GMP facility in Shenzhen;
• Personalized AI-guided life cycle management; and
• Integrated Eastern, Western, and functional medicine.
  

The clinic will focus on enhancing longevity by slowing biological aging, strengthening immunity, and providing long-term health planning, supported by partnerships with leading longevity institutions and hospitals in Japan, the United States, and Singapore.

Mr Alfred Lim, CEO of EUDA, commented:

“This is a defining moment in EUDA’s evolution. By combining an iPSC platform, expanding stem cell and t-cell therapies, the new upgraded GMP facility’s production capacity, and a fully integrated longevity clinic, we are building a comprehensive, end-to-end regenerative ecosystem. Our robust partnerships with Shenzhen Inno, GO POSB, and the introduction of leading Japanese clinical expertise, positions EUDA to capitalize on the fast-growing longevity sector and operate at the frontier of healthcare.”

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward-Looking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did EUDA (NASDAQ: EUDA) announce on December 23, 2025 about stem cell therapies?

EUDA announced the launch of a comprehensive stem cell therapy platform and upgrades to Shenzhen Inno’s cGMP facility to support iPSC and immune cell therapies.

Where and when did EUDA open its first longevity clinic?

EUDA established its first longevity clinic in Shenzhen, announced on December 23, 2025.

How will EUDA produce stem cell and T-cell therapies for the Shenzhen clinic?

EUDA is upgrading Shenzhen Inno’s cGMP facility into a production center to manufacture stem cell and T-cell immunotherapies.

What role does GO POSB and iPSC technology play in EUDA’s plan?

EUDA plans to integrate GO POSB’s iPSC platform with partners’ technologies to enable iPSC expansion and cell-based solutions.

Does EUDA already own GO POSB after the announcement?

No; EUDA announced an intention to acquire GO POSB, which indicates the acquisition is not yet completed.

What services will the Shenzhen longevity clinic offer to patients?

The clinic will offer advanced stem cell and T-cell therapies, AI-guided life-cycle management, and integrated Eastern, Western, and functional medicine.